About Us
Products
Pipeline
Science
Therapeutic Area
Investor and Media
Business Development
Collaborators
Vision, mission, strategy and values
Management
Board of Directors
Global Medical and Scientific Advisory Board
Careers
Contact
Totect ®
Savene®/Totect®
Belinostat
APO866
Zemab
APO010
mTOR
Topoisomerase II Catalytic Inhibitors
Histone Deacetylase (HDAC)
Immunotoxins
NAD+
The MegaLigand™ technology
mTOR
Scientific Publications
Glossary
Extravasation
Solid Tumours and Haematology
Basal Cell Carcinoma
Familial Adenomatous Polyposis
HER2+ Cancers
Acne
Gout
Cancer
Non Cancer
Stock Quotes
Share Information
Announcements
Presentations and events 2010
Presentations and Events 2009
Presentations and Events 2008
Presentations and Events 2007
Presentations and Events 2006
Presentations and Events 2005
Share Information
News Releases
Financial Reports
Financial Calender
Articles of Association
Analyst Coverage
Presentations and Events
Corporate Governance
Investor Relations Policy
Subscriptions
Image Bank
Contacts
Georg-Speyer-Haus
National Cancer Institute
Rigshospitalet
Astellas
CuraGen
Novartis AG
Academic Collaborators
Companies
Home
Search
Savene®/Totect®
Belinostat
APO866
Zemab
APO010
mTOR
Overview of Development programmes
This text is replaced by the Flash movie.
For an overview of HSP90, AvuganeTM, Baceca® and SavicolTM please click on the following link:
Business Development Programmes
© TopoTarget
Sitemap
Disclaimer
TopoTarget A/S - Fruebjergvej 3 - 2100 København Ø - Denmark - Phone +45 39 17 83 92
About Us
Cancer